Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
11,72 USD | +1,03% | +1,03% | -19,51% |
Omzet 2022 | 25,9 mln. 24,23 mln. | Omzet 2023 | 42,81 mln. 40,04 mln. | Marktkapitalisatie | 17,99 mln. 16,83 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -33 mln. -30,86 mln. | Nettowinst (verlies) 2023 | -24 mln. -22,45 mln. | EV/omzet 2022 | 1,21 x |
Nettoliquiditeiten 2022 | 46,07 mln. 43,08 mln. | Nettoliquiditeiten 2023 | 26,37 mln. 24,66 mln. | EV/omzet 2023 | -0,2 x |
K/w-verhouding 2022 |
-2,32
x | K/w-verhouding 2023 |
-0,67
x | Werknemers | 48 |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 92,57% |
Recentste transcriptie over Pieris Pharmaceuticals, Inc.
1 dag | +1,03% | ||
1 week | +1,03% | ||
Lopende maand | -20,03% | ||
1 maand | -22,07% | ||
3 maanden | -10,67% | ||
6 maanden | -39,59% | ||
Lopend jaar | -19,51% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 01-01-10 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 01-12-17 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 59 | 20-09-16 | |
James Geraghty
CHM | Chairman | 70 | 22-05-17 |
Michael Richman
BRD | Director/Board Member | 63 | 17-12-14 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 11,72 | +1,03% | 16 980 |
25-04-24 | 11,6 | -2,77% | 28 528 |
24-04-24 | 11,93 | -0,58% | 40 170 |
23-04-24 | 12 | +2,67% | 115 544 |
22-04-24 | 11,69 | +0,76% | 23 548 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:00 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-19,51% | 14,49 mln. | |
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |